A Study of AZD0120 in Autoimmune Diseases

Part of paid clinical trials in Tucson, Arizona.

Sponsor
AstraZeneca
Study ID
NCT07295847
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • AZD0120 — BIOLOGICAL
    CD19/BCMA Autologous CAR T-cell therapy product

Study Details

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Key Dates

Start date
Jan 9, 2026
Status verified
May 2026
Primary completion
Feb 22, 2028
Completion
Feb 22, 2028

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: AZD0120 Regimen 1
    Participants will receive an infusion of AZD0120 Regimen 1.
  • Experimental: AZD0120 Regimen 2
    Participants will receive an infusion of AZD0120 Regimen 2.

Primary Outcome Measure

Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) [ Time Frame: 1 year ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
Research SiteTucsonArizona85719-
Research SiteStanfordCalifornia94305-5847-
Research SiteChicagoIllinois60637-
Research SiteAnn ArborMichigan48109-
Research SiteSt LouisMissouri63110-
Research SiteNew YorkNew York10032-
Research SiteChapel HillNorth Carolina27599-
Research SiteSeattleWashington98104-

Find similar trials in Tucson, AZ

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Research Site· Tucson, AZResearch Site· Stanford, CAResearch Site· Chicago, ILResearch Site· Ann Arbor, MIResearch Site· St Louis, MOResearch Site· New York, NY

Related Studies